Company intelligence / Profile preview

Gradiant Bioconvergence

Ownership: Private
Development stage: Preclinical

Overview

Gradiant Bioconvergence is an active biotech platform company focused on discovering novel drug-resistant oncology targets and microbiome-related targets. They leverage proprietary patient-derived organoid (PDO) and co-culture systems to identify new drug candidates and understand resistance mechanisms in cancer, particularly EGFR inhibitor resistance. They are also involved in probiotics for therapeutic and functional food applications.

Therapeutic areas: OncologyGastroenterology
Modalities: Patient-derived organoids (PDOs)Co-culture systems (immune cells, cancer-associated fibroblasts)Probiotics (therapeutic and functional food applications)
Industry: Biotech

Drug pipeline

1 asset

GBC-11004

Preclinical

Beyond the preview

Go deeper on Gradiant Bioconvergence.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gradiant Bioconvergence.

Explore the full profile